Prestige BioPharma Limited
KSE:950210.KS
13500 (KRW) • At close September 13, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) KRW.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|
| Omzet
| 161.841 | 0 | 0 | 0 | 2,089.006 | 0 |
| Kosten van de omzet
| 11,658.824 | 3,869.223 | 1,667.164 | 1,185.412 | 755.331 | 240.237 |
| Brutowinst
| -11,496.983 | -3,869.223 | -1,667.164 | -1,185.412 | 1,333.675 | -240.237 |
| Brutowinstmarge
| -71.039 | 0 | 0 | 0 | 0.638 | 0 |
| Onderzoek- en ontwikkelingskosten
| 40,914.136 | 17,708.937 | 10,130.377 | 4,198.732 | 2,322.557 | 1,365.626 |
| Algemene en administratieve kosten
| 28,720.182 | 24,258.631 | 600.86 | 1,152.139 | 0 | 0 |
| Verkoop- en marketingkosten
| 10,877.046 | 18,587.431 | 8,711.365 | 5,052.51 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 39,597.228 | 42,846.062 | 9,312.225 | 6,204.649 | 3,415.225 | 1,629.44 |
| Overige kosten
| 73,476.789 | 15,670.177 | 9,071.779 | 4,668.467 | 0 | 0 |
| Bedrijfskosten
| -905.396 | 58,516.239 | 18,384.004 | 10,873.116 | 5,737.782 | 2,995.066 |
| Bedrijfsresultaat
| -69,572.693 | -58,516.24 | -18,384.005 | -10,873.118 | -4,404.107 | -3,235.304 |
| Bedrijfsresultaat ratio
| -429.883 | 0 | 0 | 0 | -2.108 | 0 |
| Totaal overige inkomsten en kosten netto
| 67,477.206 | -152,133.235 | 11,027.146 | -4,025.275 | 3,143.963 | 1,006.984 |
| Inkomen voor belasting
| -2,095.487 | -210,649.475 | -7,356.859 | -14,898.393 | -1,260.144 | -2,228.32 |
| Inkomen voor belasting ratio
| -12.948 | 0 | 0 | 0 | -0.603 | 0 |
| Belastingkosten
| 763.278 | 800.662 | 34.077 | 98.473 | 187.343 | -0 |
| Nettowinst
| 17,569.286 | -211,450.137 | -7,390.936 | -14,996.866 | -1,447.487 | -2,228.32 |
| Nettowinstmarge
| 108.559 | 0 | 0 | 0 | -0.693 | 0 |
| WPA (Winst Per Aandeel)
| 292.58 | -3,518.53 | -24.6 | -49.91 | -4.82 | -7.42 |
| Verwaterde WPA
| 292.58 | -3,518.53 | -24.6 | -49.91 | -4.82 | -7.42 |
| EBITDA
| 25,076.228 | -51,285.24 | -20,763.936 | -7,068.276 | -3,830.428 | -2,995.066 |
| EBITDA ratio
| 154.944 | 0 | 0 | 0 | -1.834 | 0 |